Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective StudyHiroki Ishihara, Kazunari Tanabe, Hidekazu Tachibana et al.|Targeted Oncology|2021Cited by 9